Article Text

Download PDFPDF
Correspondence to: ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al
  1. Rachael Mary Flood1,
  2. Richard Conway2,
  3. Colm Kirby1,
  4. Diana Gheta1,
  5. David J Kane1,
  6. Ronan H Mullan1
  1. 1 Department of Rheumatology, Tallaght University Hospital, Dublin, Ireland
  2. 2 Rheumatology, Saint James's Hospital, Dublin, Ireland
  1. Correspondence to Dr Rachael Mary Flood, Department of Rheumatology, Tallaght University Hospital, Dublin 24, Ireland; floodrm{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The recently published Global Rheumatology Alliance (GRA) physician-reported registry provides important information on COVID-19 disease morbidity patterns including characteristics associated with hospitalisation for patients with inflammatory rheumatic diseases (IRDs). Key findings reported include higher odds of hospitalisation with glucocorticoid exposure and comparatively decreased odds with anti-tumour necrosis factor biological disease modifying anti-rheumatic drugs (bDMARDs).1 Although this registry data are exceptionally valuable, the lack of a denominator IRD population at risk has meant it is unable to provide information on the true rate of COVID-19 disease incidence in IRDs. COVID-19 data published from New York and northeast Italy suggests incidence rates in IRD which are no different from the general population.2 3 Furthermore, GRA and EULAR reported hospitalisation rates of 46% and 49% for …

View Full Text


  • Contributors All authors obtained authorship and contributed to the data collection and analysis.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Provenance and peer review Not commissioned; internally peer reviewed.